At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
HBM9036 0.25% Ophthalmic Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of HBM9036 Ophthalmic Solution Versus Placebo in Subjects With Moderate to Severe Dry Eye
In Brief
A Phase 2 clinical trial evaluating HBM9036 0.25% Ophthalmic Solution and placebo for Dry Eye. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of HBM9036 Ophthalmic Solution versus placebo in the treatment of dry eye
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartMar 2019
Primary CompletionJul 2019
Study CompletionJul 2019
First PostedSep 2019
TodayJul 2026
First PostedSep 17, 2019
Enrollment StartMar 22, 2019
Primary CompletionJul 3, 2019
Study CompletionJul 10, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.8 years ago
Interventions
HBM9036 0.25% Ophthalmic Solutiondrug
Ophthalmic Solution
placebodrug
Ophthalmic Solution